A project manager is developing the risk management plan for a new pharmaceutical drug development project.
The sponsor has emphasized that while innovation is key, the project must not jeopardize regulatory approval.
This implies a very low tolerance for any risks related to compliance and safety.
Which component of the risk management plan is MOST directly concerned with defining these acceptable levels of risk-taking?